| P50 | author | Olivier Hermine | Q28322530 |
| | Hans Joachim Deeg | Q75039559 |
| | Livio Pagano | Q88052025 |
| | Bernd Gruhn | Q89749384 |
| | Uday R Popat | Q89893020 |
| | Gandhi Damaj | Q91137935 |
| | Cem Akin | Q42415677 |
| | Ibrahim Yakoub-Agha | Q58191171 |
| | Martin Bornhäuser | Q61053345 |
| P2093 | author name string | John Barrett | |
| | Miguel-Angel Perales | |
| | Peter Valent | |
| | Lucy A Godley | |
| | Michael Doubek | |
| | Celalettin Ustun | |
| | Jack W Hsu | |
| | Wael Saber | |
| | Wolfgang R Sperr | |
| | Edwin P Alyea | |
| | Werner Rabitsch | |
| | Christoph Schmid | |
| | Eleni Tholouli | |
| | Tanja Gromke | |
| | Vinod Pullarkat | |
| | Bart L Scott | |
| | Daniel Weisdorf | |
| | Andreas Reiter | |
| | Maria Teresa Van Lint | |
| | Ryotaro Nakamura | |
| | Ryan Shanley | |
| | Steven Devine | |
| | Esperanza B Papadopoulos | |
| | William J Hogan | |
| | Alexandra Böhm | |
| | Gregory Vercellotti | |
| | Sebastian Kreil | |
| | Tor Shwayder | |
| | Hans Hagglund | |
| | Faezeh Legrand | |
| | Tsiporah Shore | |
| | Herrad Baurmann | |
| | Andrew Gilman | |
| | Eva Maria Wagner | |
| | Robert Stuart | |
| P2860 | cites work | Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis | Q22001442 |
| | Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study | Q27824856 |
| | Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management | Q27851694 |
| | Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study | Q28139696 |
| | Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) | Q28209814 |
| | Kit as a human oncogenic tyrosine kinase | Q28297098 |
| | Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors | Q33384073 |
| | AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. | Q33762738 |
| | Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder | Q33784323 |
| | Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome | Q33813439 |
| | Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission | Q33931553 |
| | Diagnostic criteria and classification of mastocytosis: a consensus proposal | Q33948617 |
| | Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia | Q33990856 |
| | The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission | Q34033852 |
| | Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. | Q34049208 |
| | Mast cells process bacterial Ags through a phagocytic route for class I MHC presentation to T cells | Q34062282 |
| | Inducible MHC class II expression by mast cells supports effector and regulatory T cell activation | Q34068978 |
| | Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components | Q34300709 |
| | Mast cells are essential intermediaries in regulatory T-cell tolerance | Q34559099 |
| | Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study | Q34570206 |
| | Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden | Q34919228 |
| | KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients | Q61818977 |
| | Rapid engraftment of mast cells of donor origin in a case of acute myeloid leukemia with mast cell leukemia after allogeneic stem cell transplantation | Q64048696 |
| | Response to interferon alfa-2b in a patient with systemic mastocytosis | Q67531413 |
| | Persistence of systemic mastocytosis after allogeneic bone marrow transplantation in spite of complete remission of the associated myelodysplastic syndrome | Q67820466 |
| | Intrathyroidal mast cells express major histocompatibility complex class-II antigens | Q69109442 |
| | c-kit point mutation of extracellular domain in patients with myeloproliferative disorders | Q70883308 |
| | Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm | Q70972826 |
| | Origin of human mast cells: development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation | Q72776805 |
| | Evidence for a graft-versus-mast-cell effect after allogeneic bone marrow transplantation | Q80378735 |
| | Mast cell leukemia: a report of ten cases | Q80439501 |
| | The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia | Q81538179 |
| | A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis | Q82207899 |
| | Systemic mastocytosis | Q83304407 |
| | Death from mast cell leukemia: a young patient with longstanding cutaneous mastocytosis evolving into fatal mast cell leukemia | Q83432864 |
| | Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology | Q84064985 |
| | Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia | Q84342632 |
| | Delayed graft-versus-mast-cell effect on systemic mastocytosis with associated clonal haematological non-mast cell lineage disease after allogeneic transplantation | Q85241534 |
| | Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. | Q34987900 |
| | Recent advances in allogeneic hematopoietic stem-cell transplantation | Q35041223 |
| | Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria | Q35101794 |
| | Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. | Q35848377 |
| | Clonality and molecular pathogenesis of mastocytosis. | Q36182758 |
| | International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. | Q36730397 |
| | Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies | Q36819337 |
| | GVHD the nuts and bolts | Q37007263 |
| | Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis | Q37247964 |
| | Mechanisms of mast cell signaling in anaphylaxis | Q37457346 |
| | Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns | Q37811681 |
| | Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. | Q37884959 |
| | Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: a case review | Q37955869 |
| | Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia | Q38028808 |
| | Mast cell leukemia | Q38067698 |
| | Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. | Q40048837 |
| | Expression of functional major histocompatibility complex class II molecules on HMC-1 human mast cells. | Q40989006 |
| | High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V. | Q41130396 |
| | Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases | Q41678277 |
| | Systemic mastocytosis with associated clonal hematological non‐mast‐cell lineage disease: Analysis of clinicopathologic features and activating c‐kit mutations | Q43493292 |
| | Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. | Q43745319 |
| | Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies | Q44258165 |
| | Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. | Q44471803 |
| | A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib | Q44534510 |
| | Imatinib for systemic mast-cell disease | Q44558628 |
| | Cladribine therapy for systemic mastocytosis. | Q44559230 |
| | Hidden mastocytosis in acute myeloid leukemia with t(8;21)(q22;q22). | Q46039976 |
| | Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis. | Q46236337 |
| | Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. | Q46262657 |
| | Quantitation of minimal residual disease in acute myeloid leukemia by tryptase monitoring identifies a group of patients with a high risk of relapse | Q46706257 |
| | PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects | Q46724516 |
| | Myelomastocytic leukemia: evidence for the origin of mast cells from the leukemic clone and eradication by allogeneic stem cell transplantation | Q46735020 |
| | Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity | Q46819255 |
| | Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone | Q47592508 |
| | Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). | Q52569827 |
| | Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML. | Q53094956 |
| | Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. | Q54578171 |
| | How I treat patients with advanced systemic mastocytosis. | Q54648770 |
| P433 | issue | 29 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | stem cell transplantation | Q65592366 |
| P304 | page(s) | 3264-3274 | |
| P577 | publication date | 2014-08-25 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Hematopoietic stem-cell transplantation for advanced systemic mastocytosis | |
| P478 | volume | 32 | |